Fulcrum Therapeutics, Inc. FULC · SEC Filings

website

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-i...

Price3.72

Market Cap284.14 M

Float75.61 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

Prospectus

TYPE

HEADLINE

FILED AT

424B3

OFFERING - OTHER | Offering amount: $245,000,000 | Price: $3.740

Nov 4, 2026

425

Form 425 - Prospectuses and communications, business combinations

Aug 17, 2026

425

Form 425 - Prospectuses and communications, business combinations

Aug 17, 2026

425

Form 425 - Prospectuses and communications, business combinations

Aug 17, 2026

424B5

REGISTERED OFFERING

Dec 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $150,000,000 | Bank: J.P. Morgan, Leerink Partners, Cantor Oppenheimer & Co., Truist Securities

Dec 8, 2025

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

May 7, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 19, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT